Elaine Sullivan is CEO of Dargle Therapeutics, the Executive Chairman of Keltic Pharma and a Non-Executive Director at Open Orphan, IP Group plc and Active Biotech AB and is a member of the Supervisory Board at Evotec AG which is listed on the Frankfurt Stock Exchange. She has over 25 years of international experience working in the pharmaceutical and biotech industry. Elaine has worked as part of the most senior management teams in R&D at Eli Lilly and AstraZeneca. She served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, USA, where she led a global workforce delivering access to business-critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly’s Capital Fund partners.
Prior to joining Eli Lilly, Dr Sullivan held various positions in the area of drug discovery and development at AstraZeneca including Vice President R&D, New Opportunities. In this role, she led AstraZeneca‘s virtual therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic. She also held the role of Vice-President, Science & Technology with the focus on acquiring new technologies which led to decreased attrition of compounds failing for toxicity and efficacy reasons in the clinic.
During her career, she gained extensive knowledge of various aspects of drug discovery and development having developed new molecules in virology, cancer and ophthalmology. She co-founded Carrick Therapeutics a European oncology company which has raised €100 million. She has successfully delivered over 250 collaborations and transactions including spinouts, joint ventures, strategic partnerships and acquisitions.
Dr Sullivan holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor’s degree in Molecular Biology from the University of Glasgow, UK.